公开(公告)号：US20190203306A1

公开(公告)日：2019-07-04

申请号：US16353386

申请日：2019-03-14

Applicant: BIOMERIEUX

Inventor： Maud Arsac ,  Bertrand Bonnaud ,  Francois Mallet ,  Jean-Philippe Pichon

IPC: C12Q1/70 ,  C12Q1/6886

CPC classification number: C12Q1/702 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.

公开(公告)号：US10240213B2

公开(公告)日：2019-03-26

申请号：US13739447

申请日：2013-01-11

Applicant: BIOMERIEUX

Inventor： Maud Arsac ,  Bertrand Bonnaud ,  Francois Mallet ,  Jean-Philippe Pichon

IPC: C12Q1/6886 ,  C12Q1/70

Abstract: The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.

公开(公告)号：US11085091B2

公开(公告)日：2021-08-10

申请号：US16353386

申请日：2019-03-14

Applicant: BIOMERIEUX

Inventor： Maud Arsac ,  Bertrand Bonnaud ,  Francois Mallet ,  Jean-Philippe Pichon

IPC: C12Q1/70 ,  C12Q1/6886

Abstract: The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.